UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2014

Commission File Number                         

 

 

Novogen Limited

(Translation of registrant’s name into English)

 

 

16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  þ             Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  ¨     No  þ

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

 

 

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novogen Limited (Registrant)

Lionel Mateo

Lionel Mateo

Company Secretary

Date 19 November 2014


 

NOVOGEN LIMITED

(ASX: NRT)

   LOGO

ASX RELEASE

18 November 2014

CLEANSING NOTICE

We refer to the issue of a convertible security by Novogen Limited (Novogen) on 18 October 2013. Pursuant to a notice of conversion of a portion of the convertible security representing in aggregate $25,000, Novogen issued 242,719 ordinary shares to Merrill Lynch (Australia) Nominees Pty Limited ACN 003 925 031 FBO Hudson Bay Master Fund Limited on 18 November 2014 (Shares).

For the purposes of section 708A(5)(e)(i) of the Corporations Act 2001 (Cth) (Corporations Act) Novogen gives notice that:

 

  1. Novogen issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;

 

  2. as at the date of this notice, Novogen has complied with:

 

  (a) the provisions of Chapter 2M of the Corporations Act as they apply to Novogen; and

 

  (b) section 674 of the Corporations Act; and

 

  3. as at the date of this notice, there is no information that is “excluded information” (as defined in subsections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by Novogen.

Yours faithfully,

 

LOGO

Lionel Mateo

Company Secretary

NOVOGEN LTD – ACN 063 259 754 |16-20 Edgeworth David Ave, Hornsby, NSW, 2077

P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388 | www.novogen.com


 

NOVOGEN LIMITED

(ASX: NRT)

   LOGO

ASX RELEASE

18 November 2014

CLEANSING NOTICE

We refer to the announcement regarding the issue of security by Novogen Limited (Novogen) following completion of the capital raise released on Wednesday 12 November 2014. Due to late clearance of some payments, the capital raise final numbers were adjusted to $1,854,598 being 16,859,988 ordinary shares at $0.110 per share. Each share comes with an attached 1 year unlisted option with an exercise price of $0.125. The capital raise was conducted on the basis of Shareholders’ approval to issue up to 80 million shares and up to 80 million options received on 13 August 2014.

For the purposes of section 708A(5)(e)(i) of the Corporations Act 2001 (Cth) (Corporations Act) Novogen gives notice that:

 

  1. Novogen issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;

 

  2. as at the date of this notice, Novogen has complied with:

 

  (a) the provisions of Chapter 2M of the Corporations Act as they apply to Novogen; and

 

  (b) section 674 of the Corporations Act; and

 

  3. as at the date of this notice, there is no information that is “excluded information” (as defined in subsections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by Novogen.

Yours faithfully,

 

LOGO

Lionel Mateo

Company Secretary

NOVOGEN LTD – ACN 063 259 754 |16-20 Edgeworth David Ave, Hornsby, NSW, 2077

P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388 | www.novogen.com

Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kazia Therapeutics Charts.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kazia Therapeutics Charts.